|
1
|
Nogová L, Rudiger T and Engert A: Biology,
clinical course and management of nodular lymphocyte-predominant
hodgkin lymphoma. Hematology Am Soc Hematol Educ Program.
2006:266–272. 2006.
|
|
2
|
Illés A, Simon Z, Tóth E, Rosta A,
Miltényi Z and Molnár Z: Nodular lymphocyte predominant Hodgkin
lymphoma (NLPHL)-clinicopathological features based on the data of
two Hungarian lymphoma centres. Pathol Oncol Res. 14:411–421.
2008.
|
|
3
|
Savage KJ, Skinnider B, Al-Mansour M, Sehn
LH, Gascoyne RD and Connors JM: Treating limited-stage nodular
lymphocyte predominant Hodgkin lymphoma similarly to classical
Hodgkin lymphoma with ABVD may improve outcome. Blood.
118:4585–4590. 2011.
|
|
4
|
Chen RC, Chin MS, Ng AK, et al:
Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient
outcomes from a large, single-institution series with long
follow-up. J Clin Oncol. 28:136–141. 2010.
|
|
5
|
Al-Mansour M, Connors JM, Gascoyne RD,
Skinnider B and Savage KJ: Transformation to aggressive lymphoma in
nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol.
28:793–799. 2010.
|
|
6
|
Biasoli I, Stamatoullas A, Meignin V, et
al: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term
study and analysis of transformation to diffuse large B-cell
lymphoma in a cohort of 164 patients from the Adult Lymphoma Study
Group. Cancer. 116:631–639. 2010.
|
|
7
|
Nogová L, Reineke T, Brillant C, et al:
Lymphocyte-predominant and classical Hodgkin’s lymphoma: a
comprehensive analysis from the German Hodgkin Study Group. J Clin
Oncol. 26:434–439. 2008.
|
|
8
|
Harris NL, Jaffe ES, Diebold J, et al:
World Health Organization Classification of neoplastic diseases of
hematopoetic and lymphoid tissues: Report of the Clinical Advisory
Committee Meeting - Airlie House, Virginia, November 1997. J Clin
Oncol. 17:3835–3849. 1999.
|
|
9
|
Xing KH, Connors JM, Lai A, et al: The
outcome of advanced stage nodular lymphocyte predominant Hodgkin’s
lymphoma (NLPHL) compared to classical Hodgkin’s lymphoma (CHL): a
matched pair analysis. Blood. 123:3567–3573. 2014.
|
|
10
|
Hagspiel KD: Manifestation of Hodgkin’s
lymphoma in an adrenal myelolipoma. Eur Radiol. 15:1757–1759.
2005.
|
|
11
|
Bourne AE, Bell SW, Wayment RO and
Schwartz BF: Primary Hodgkin lymphoma of the adrenal gland: a
unique case presentation. Cn J Urol. 16:4694–4696. 2009.
|
|
12
|
Szczepanowski M, Masqué-Soler N, Oschlies
I, Schmidt W, Lück A and Klapper W: Composite lymphoma of nodular
lymphocyte-predominant and classical Hodgkin lymphoma-Epstein-Barr
virus association suggests divergent pathogenesis despite clonal
relatedness. Hum Pathol. 44:1434–1439. 2013.
|
|
13
|
Engert A, Haverkamp H, Kobe C, et al:
Reduced-intensity chemotherapy and PET-guided radiotherapy in
patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a
randomised, open-label, phase 3 non-inferiority trial. Lancet.
379:1791–1799. 2012.
|
|
14
|
Anagnostopoulos I, Hansmann ML, Franssila
K, et al: European Task Force on Lymphoma project on lymphocyte
predominance Hodgkin disease: histologic and immunohistologic
analysis of submitted cases reveals 2 types of Hodgkin disease with
a nodular growth pattern and abundant lymphocytes. Blood.
96:1889–1899. 2000.
|
|
15
|
Eichenauer DA, Fuchs M, Pluetschow A,
Klimm B, et al: Phase 2 study of rituximab in newly diagnosed stage
IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from
the German Hodgkin Study Group. Blood. 118:4363–4365. 2011.
|
|
16
|
Eichenauer DA, Engert A and Dreyling M;
ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 22(Suppl 6): Svi55–Svi58. 2011.
|
|
17
|
Wirth A, Yuen K and Barton M: Long-term
outcome after radiotherapy alone for lymphocyte-predominant Hodgkin
lymphoma: a retrospective multicenter study of the Australasian
Radiation Oncology Lymphoma Group. Cancer. 104:1221–1229. 2005.
|
|
18
|
Nogova L, Reineke T, Eich HT, et al:
Extended field radiotherapy, combined modality treatment or
involved field radiotherapy for patients with stage IA
lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis
from German Hodgkin Study Group (GHSG). Ann Oncol. 16:1683–1687.
2005.
|
|
19
|
Specht L, Yahalom J, Illidge T, et al:
Modern radiation therapy for Hodgkin lymphoma: field and dose
guidelines from the International Lymphoma Radiation Oncology Group
(ILROG). Int J Radiat Oncol Biol Phys. DOI:
10.1016/j.ijrobp.2013.05.005
|
|
20
|
Savage KJ, Hoskins P, Klasa R, et al: ABVD
chemotherapy is essential for optimal treatment of limited stage
nodular lymphocyte predominant Hodgkin lymphoma. Hematologica.
92(Suppl 5): 27–28. 2007.
|
|
21
|
Meyer RM, Gospodarowicz MK, Connors JM, et
al: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group:
ABVD alone versus radiation-based therapy in limited-stage
Hodgkin’s lymphoma. N Engl J Med. 366:399–408. 2012.
|
|
22
|
Pellegrino B, Terrier-Lacombe MJ, Oberlin
O, et al: Lymphocyte-predominant Hodgkin’s lymphoma in children:
therapeutic abstention after initial lymph node resection - a Study
of the French Society of Pediatric Oncology. J Clin Oncol.
21:2948–2952. 2003.
|
|
23
|
Mauz-Körholz C, Gorde-Grosjean S,
Hasenclever D, et al: Resection alone in 58 children with limited
stage, lymphocyte-predominant Hodgkin lymphoma-experience from the
European network group on pediatric Hodgkin lymphoma. Cancer.
110:179–185. 2007.
|
|
24
|
Ekstrand BC, Lucas JB, Horwitz SM, et al:
Rituximab in lymphocyte-predominant Hodgkin disease: results of a
phase 2 trial. Blood. 101:4285–4289. 2003.
|
|
25
|
Schulz H, Rehwald U, Morschhauser F, et
al: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma:
long-term results of a phase 2 trial by the German Hodgkin Lymphoma
Study Group (GHSG). Blood. 111:109–111. 2008.
|
|
26
|
Hoppe RT, Advani RH, Ai WZ, et al: Hodgkin
lymphoma, version 2.2012 featured updates to the NCCN guidelines. J
Natl Compr Canc Netw. 10:589–597. 2012.
|
